期刊文献+

雄激素受体在前列腺增生和前列腺癌组织中的表达 被引量:6

Expressions of androgen receptor in benign prostatic hyperplasia with High PSA value and prostatic cancer
下载PDF
导出
摘要 目的探讨雄激素受体(AR)在前列腺特异性抗原高的良性前列腺增生(BPH)组织和前列腺癌(PCa)组织中表达的意义。方法采用免疫组化和RT-PCR法研究AR在32例前列腺特异性抗原(PSA)≥10 ng/mL的BPH(简称高PSA组)、40例PCa组织中表达的情况;32例PSA<10 ng/mL的BPH(简称低PSA组)组织为对照组。结果低PSA组、高PSA组、PCa组AR表达的阳性率分别为84.38%、93.75%、65.00%,相互比较,差异均有统计学意义(P<0.05)。AR在高PSA组上皮、间质组织中的表达高于低PSA组和PCa组织(P<0.05)。高分化癌、中分化癌、低分化癌的AR表达的阳性率分别为66.67%5、5.56%、30.00%,高、中分化癌的AR表达的阳性率比低分化癌高(P<0.05)。早期前列腺癌的AR表达阳性率(68.75%)比晚期前列腺癌(41.67%)高(P<0.05)。早期前列腺癌的AR mRNA表达量比晚期前列腺癌高(P<0.05);高、中分化癌的AR mRNA表达量比低分化癌高(P<0.05)。结论AR在高PSA组前列腺增生组织中表达增高,提示其在前列腺增生中的过表达可能是PSA增高的又一因素。AR的表达与肿瘤分级、分期相关。 Objective To investigate the expressions of androgen receptor (AR) in benign prostatic hyperplasia (BPH) with high PSA value and prostatic cancer(PCa) tissues and its clinical significance. Methods AR expressions were determined in 32 human prostatic hyperplasia tissue specimens( PSA≥ 10 ng/mL group) ( the high PSA group) and 40 prostatic cancer tissues by immunohistochenfical and RT-PCR methods. 32 human prostatic hyperplasia tissue specimens(PSA 〈 10 ng/mL group) (the low PSA group) served as the control group. Results The positive staining rates of AR in the high PSA group, the low PSA group and the PCa group were respectively 93.75 %, 84.38 % and 65.00 % ( P 〈 0.05). Positive expressions of AR were much higher in epithelial and mysenchymal tissues of the high PSA group than in the low PSA group and the PCa group( P 〈 0.05). The AR expression was significantly higher in well (66.67%) or moderately (55.56%) differentiated adenocarcinoma than that in poorly differentiated tumors (30.00%)(P 〈 0.05), and it was higher in tumors at early stages (68.75%) than in tumors at advanced stages (41.67%)(P 〈 0.05). AR mRNA expression was also determined by RT-PCR, and it was much higher in epithelial and mysenchymal tissues of the high PSA group than in prostatic tissues of the low PSA group (P 〈 0.05). Also it was significantly higher in well or moderately differentiated adenocarcinoma than in poorly differentiated tumors ( P 〈 0.05) and higher in tumors at early stages than in tumors at advanced stage ( P 〈 0.05). Conclusions AR is high in the high BPH with PSA group, indicating AR plays an important role in the regulation of PSA of prostatic tissues and therefore AR might be a causative factor in high PSA value. The expression of AR is related to tumor grades or stages.
出处 《山东大学学报(医学版)》 CAS 北大核心 2008年第5期506-509,共4页 Journal of Shandong University:Health Sciences
关键词 前列腺增生 前列腺肿瘤 雄激素受体 前列腺特异性抗原 Prostatic hyperplasia Prostatic neoplasms Androgen receptor Prostate-specific antigen
  • 相关文献

参考文献12

  • 1Chatterjee B. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer[ J]. Mol Cell Biochem, 2003, 253 ( 1 ) : 89-101.
  • 2Brinkmann A O, Jeuster G, Kuiptur G G, et al. The human androgen receptor: structure/function relationship in normal and pathological situalions[J]. J Steroid Biochem Mol Biol, 1992,41(2):361-364.
  • 3Riegman P H, Vlietstra R J, Korput J A, et al. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element[ J]. Mol Endocrinol, 1991, 5 ( 12): 1921-1930.
  • 4张元芳.前列腺特异性抗原检测与前列腺癌之间关系的思考[J].上海医学,2005,28(5):355-356. 被引量:4
  • 5Hammerer P, Huland H. Systematic sextant biopsies in 651 patients referred for prostate evaluation[J]. J Urol, 1994, 151 (1):99-102.
  • 6施作霖,林艳清,张延榕,李燕辉,陈梓甫.前列腺癌雄激素受体表达与细胞凋亡的关系[J].临床与实验病理学杂志,2001,17(2):136-138. 被引量:2
  • 7Sweat S D, Pacelli A, Bergstralh E J, et al. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer [J]. J Urol, 1999, 161(4):1229-1232.
  • 8Culig Z, Hobisch A, Cronauer M V, et al. Activation of the androgen receptor by polypeptide growth factors and cellular regulators[J]. World J Urol, 1995, 13(4):285-289.
  • 9王晓慧,谢靖,陈光椿,卢建.前列腺癌患者雄激素受体N端AF1区的突变研究[J].中华泌尿外科杂志,2000,21(12):712-715. 被引量:7
  • 10Heinlein C A, Chang C. Androgen receptor in prostate cancer[J]. Endocr Rev, 2004, 25(2): 276-308.

二级参考文献13

  • 1谢庆祥.雄激素受体与前列腺癌关系的研究进展[J].国外医学(泌尿系统分册),1997,17(1):11-13. 被引量:3
  • 2王晓慧,中国病理生理杂志,2000年,16卷,8页
  • 3Irvine R A,Cancer Res,1995年,55卷,1937页
  • 4Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med, 1987, 317: 909-916.
  • 5Mitka M. Is PSA testing still useful? JAMA, 2004, 292:2326-2327.
  • 6Stamey TA, Caldwell M, McNeal JE, et al. The prostate specific antigen era in the United States is over for prostate cancer:what happened in the last 20 years? J Urol, 2004, 172:1297-1301.
  • 7Sakr WA, Grignon DJ, Haas GP, et al. Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol, 1996,30: 138-144.
  • 8Rich AR. On the frequency of occurrence of occult carcinoma of the prostate. J Urol, 1935,33: 215.
  • 9McNaughton Collins M, Ransohoff DF, Barry MJ. Early detection of prostate cancer. Serendipity strikes again. JAMA,1997, 278: 1516-1519.
  • 10Punglia RS, DAmico AV, Catalona WJ, et al. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med, 2003, 349: 335-342.

共引文献10

同被引文献43

引证文献6

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部